Robeco Institutional Asset Management B.V. Has $19.34 Million Stock Position in CVS Health Co. (NYSE:CVS)

Robeco Institutional Asset Management B.V. decreased its holdings in CVS Health Co. (NYSE:CVS) by 59.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 244,920 shares of the pharmacy operator’s stock after selling 365,396 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in CVS Health were worth $19,339,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the stock. Atticus Wealth Management LLC lifted its stake in shares of CVS Health by 149.0% in the fourth quarter. Atticus Wealth Management LLC now owns 366 shares of the pharmacy operator’s stock worth $29,000 after acquiring an additional 219 shares during the period. USA Financial Formulas boosted its stake in shares of CVS Health by 573.2% in the 4th quarter. USA Financial Formulas now owns 377 shares of the pharmacy operator’s stock valued at $30,000 after purchasing an additional 321 shares during the last quarter. Cornerstone Planning Group LLC increased its position in shares of CVS Health by 111.5% during the third quarter. Cornerstone Planning Group LLC now owns 461 shares of the pharmacy operator’s stock worth $32,000 after buying an additional 243 shares during the period. ZRC Wealth Management LLC lifted its holdings in CVS Health by 400.0% in the fourth quarter. ZRC Wealth Management LLC now owns 500 shares of the pharmacy operator’s stock valued at $39,000 after buying an additional 400 shares during the period. Finally, Coston McIsaac & Partners boosted its position in CVS Health by 42.6% during the fourth quarter. Coston McIsaac & Partners now owns 539 shares of the pharmacy operator’s stock valued at $42,000 after acquiring an additional 161 shares during the last quarter. 80.66% of the stock is owned by institutional investors.

Analysts Set New Price Targets

CVS has been the topic of a number of recent analyst reports. Leerink Partnrs downgraded CVS Health from an “outperform” rating to a “market perform” rating in a research note on Wednesday, May 1st. Cantor Fitzgerald lowered CVS Health from an “overweight” rating to a “neutral” rating and cut their price target for the stock from $87.00 to $58.00 in a report on Wednesday, May 1st. UBS Group lowered CVS Health from a “buy” rating to a “neutral” rating and cut their price target for the stock from $85.00 to $60.00 in a report on Thursday, May 2nd. StockNews.com lowered CVS Health from a “buy” rating to a “hold” rating in a report on Thursday, February 15th. Finally, Royal Bank of Canada cut their price target on CVS Health from $86.00 to $84.00 and set an “outperform” rating on the stock in a report on Thursday, February 8th. Nine investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $76.75.

Insiders Place Their Bets

In other news, Director Edward J. Ludwig acquired 1,000 shares of the business’s stock in a transaction dated Thursday, May 2nd. The stock was purchased at an average cost of $53.88 per share, for a total transaction of $53,880.00. Following the acquisition, the director now owns 21,630 shares of the company’s stock, valued at $1,165,424.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.24% of the company’s stock.

CVS Health Stock Performance

Shares of NYSE:CVS traded up $0.16 during midday trading on Friday, reaching $57.68. 9,607,690 shares of the company traded hands, compared to its average volume of 15,924,059. The firm has a market capitalization of $72.41 billion, a price-to-earnings ratio of 10.14, a price-to-earnings-growth ratio of 0.55 and a beta of 0.56. The company has a quick ratio of 0.61, a current ratio of 0.81 and a debt-to-equity ratio of 0.78. The firm’s fifty day moving average price is $69.06 and its two-hundred day moving average price is $72.39. CVS Health Co. has a 12 month low of $53.70 and a 12 month high of $83.25.

CVS Health (NYSE:CVS) last announced its earnings results on Wednesday, May 1st. The pharmacy operator reported $1.31 earnings per share for the quarter, missing analysts’ consensus estimates of $1.69 by ($0.38). The business had revenue of $88.44 billion during the quarter, compared to the consensus estimate of $89.33 billion. CVS Health had a return on equity of 13.53% and a net margin of 2.03%. CVS Health’s revenue was up 3.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.20 earnings per share. On average, equities analysts expect that CVS Health Co. will post 7.02 earnings per share for the current year.

CVS Health Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, May 1st. Shareholders of record on Monday, April 22nd were paid a $0.665 dividend. The ex-dividend date of this dividend was Friday, April 19th. This represents a $2.66 dividend on an annualized basis and a yield of 4.61%. CVS Health’s dividend payout ratio is currently 46.75%.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.